SNYSanofiRunning, no new patients
A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
Plasma Cell Myeloma Refractory
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 64 (planned)
- Started
- Mar 17, 2025
- Main results expected
- Apr 1, 2027
- Fully finished
- Jul 15, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall response rate (ORR)
Measured over: 6 months after the Last Participant In (LPI) i.e., approximately 32 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06356571 · record last updated 2026-10-26 · checked 2026-11-09 15:47 UTC